MHTX: AI 评分 46/100 — AI 分析 (4月 2026)

Manhattan Scientifics, Inc. is a technology incubator focused on developing and commercializing life-enhancing technologies in the fields of nano-technologies and nano-medicine. Founded in 1992, the company operates in the United States, seeking to advance innovations in the healthcare sector.

Key Facts: AI Score: 46/100 Sector: Healthcare

公司概况

概要：

Manhattan Scientifics, Inc. operates as a technology incubator specializing in nano-technologies and nano-medicine within the healthcare sector. The company focuses on the development and commercialization of life-enhancing technologies, primarily in the United States, facing competition from established medical device companies and other emerging technology firms.

MHTX是做什么的？

Manhattan Scientifics, Inc., established in 1992 and based in New York City, functions as a technology incubator dedicated to the advancement and commercialization of life-enhancing technologies. The company's primary focus lies within the realms of nano-technologies and nano-medicine, where it seeks to develop and bring to market innovative solutions for various healthcare challenges. Originally named Grand Enterprises, Inc., Manhattan Scientifics has evolved to concentrate on identifying, developing, and commercializing early-stage technologies with high growth potential. The company's business model revolves around investing in and nurturing promising technologies until they reach a stage where they can be either spun off into separate entities, licensed to larger corporations, or further developed in-house. Manhattan Scientifics operates primarily within the United States, targeting opportunities where nano-scale technologies can provide significant improvements in medical treatments, diagnostics, and other healthcare applications. The company's success hinges on its ability to identify and develop groundbreaking technologies, navigate the complex regulatory landscape of the medical device industry, and secure the necessary funding to bring these innovations to market.

MHTX的投资论点是什么？

Manhattan Scientifics, Inc. presents a high-risk, high-reward investment opportunity due to its focus on early-stage nano-technologies and nano-medicine. The company's success is contingent on its ability to successfully develop and commercialize its technologies, which face significant regulatory and market hurdles. With a market capitalization of $0.00B and a negative P/E ratio of -0.05, the company's valuation is highly speculative. Key value drivers include successful clinical trials and regulatory approvals for its nano-medicine technologies. Upcoming catalysts include potential partnerships and licensing agreements. Potential risks include the high beta of 9.94, indicating extreme volatility, and the challenges of operating in the competitive medical device industry.

MHTX在哪个行业运营？

Manhattan Scientifics operates within the medical device industry, which is characterized by rapid innovation, stringent regulatory requirements, and intense competition. The market for nano-medicine is still in its nascent stages but is projected to experience significant growth in the coming years, driven by advancements in nanotechnology and increasing demand for targeted drug delivery systems. The company competes with established medical device companies and other emerging technology firms. Success in this industry requires significant investment in research and development, strong intellectual property protection, and the ability to navigate the complex regulatory landscape.

Medical - Devices

Healthcare

MHTX有哪些增长机遇？

Advancements in Nano-Medicine: The global nano-medicine market is projected to reach billions of dollars by 2030, driven by the increasing demand for targeted drug delivery and personalized medicine. Manhattan Scientifics can capitalize on this trend by focusing on developing innovative nano-medicine solutions for chronic diseases and cancer treatment. Successful clinical trials and regulatory approvals could significantly increase the company's valuation and market share. The timeline for realizing this opportunity depends on the progress of ongoing research and development efforts and the speed of regulatory reviews.
Strategic Partnerships and Licensing Agreements: Manhattan Scientifics can accelerate its growth by forming strategic partnerships with larger pharmaceutical and medical device companies. These partnerships can provide access to funding, expertise, and distribution channels. Licensing agreements for its nano-technology platforms can generate revenue and validate the company's technology. The timeline for securing these partnerships depends on the company's ability to demonstrate the value and potential of its technologies. This strategy is ongoing as the company seeks to expand its network and market reach.
Expansion into New Therapeutic Areas: Manhattan Scientifics can expand its focus beyond its current areas of interest and explore new therapeutic applications for its nano-technologies. This could include developing solutions for neurological disorders, cardiovascular diseases, and infectious diseases. The market for these therapeutic areas is substantial, and successful expansion could significantly increase the company's growth potential. This expansion is a long-term opportunity that requires significant investment in research and development.
Government Funding and Grants: Manhattan Scientifics can leverage government funding and grants to support its research and development efforts. Government agencies such as the National Institutes of Health (NIH) and the National Science Foundation (NSF) offer grants for innovative research in nano-technology and nano-medicine. Securing these grants can provide non-dilutive funding and validate the company's technology. The timeline for securing these grants depends on the company's ability to submit competitive proposals and meet the eligibility criteria.
Intellectual Property Protection: Manhattan Scientifics can strengthen its competitive advantage by securing strong intellectual property protection for its technologies. This includes filing patents for its nano-materials, drug delivery systems, and manufacturing processes. Strong intellectual property protection can prevent competitors from copying its technologies and provide a barrier to entry. This is an ongoing effort as the company continues to innovate and develop new technologies.

Manhattan Scientifics operates as a technology incubator, focusing on early-stage development of nano-technologies and nano-medicine.
The company's market capitalization is $0.00B, reflecting its early stage and speculative nature.
Manhattan Scientifics has a negative P/E ratio of -0.05, indicating it is not currently profitable.
The company's beta is 9.94, suggesting very high volatility compared to the market.
Manhattan Scientifics does not offer a dividend, typical for growth-focused companies in the technology sector.

MHTX提供哪些产品和服务？

Develops nano-technologies for medical applications.
Focuses on nano-medicine for targeted drug delivery.
Incubates early-stage technologies with high growth potential.
Seeks to commercialize life-enhancing technologies.
Invests in promising technologies until they are ready for market.
Aims to improve medical treatments and diagnostics through innovation.

MHTX如何赚钱？

Invests in early-stage nano-technology and nano-medicine companies.
Develops and commercializes innovative healthcare solutions.
Generates revenue through licensing agreements and potential spin-offs.

Pharmaceutical companies seeking innovative drug delivery systems.
Medical device manufacturers looking to incorporate nano-technologies.
Healthcare providers seeking advanced diagnostic and treatment tools.

Proprietary nano-technology platforms.
Expertise in nano-medicine and targeted drug delivery.
Early-stage access to innovative technologies.

什么因素可能推动MHTX股价上涨？

Upcoming: Potential partnerships with pharmaceutical companies for drug delivery systems.
Upcoming: Progress in clinical trials for nano-medicine applications.
Upcoming: Regulatory approvals for new medical devices.
Ongoing: Continued research and development in nano-technologies.
Ongoing: Efforts to secure government funding and grants.

MHTX的主要风险是什么？

Potential: Failure to obtain regulatory approvals for its technologies.
Potential: Intense competition from established medical device companies.
Potential: Limited financial resources to support research and development.
Ongoing: High volatility in stock price due to its small market capitalization.
Ongoing: Dependence on successful commercialization of its technologies.

MHTX的核心优势是什么？

Focus on innovative nano-technologies and nano-medicine.
Potential for high growth in emerging markets.
Early-stage access to promising technologies.

MHTX的劣势是什么？

Limited financial resources and small market capitalization.
Dependence on successful development and commercialization of technologies.
High risk associated with early-stage ventures.

MHTX有哪些机遇？

Strategic partnerships with larger pharmaceutical and medical device companies.
Expansion into new therapeutic areas and applications.
Government funding and grants for research and development.

MHTX面临哪些威胁？

Intense competition from established medical device companies.
Stringent regulatory requirements and lengthy approval processes.
Potential for technology obsolescence and market disruption.

MHTX的竞争对手是谁？

BioLife Solutions Inc — Provides biopreservation tools and services. — (BIOIF)
CBL International Limited — Operates as a logistics solution provider. — (CBGL)
Immuron Limited — Develops and commercializes oral immunotherapy products. — (IMMB)
InSitu Biologics Inc — Focuses on developing innovative drug delivery systems. — (INSD)
iPads Healthcare Inc — Offers telehealth and remote patient monitoring solutions. — (IPAH)

Key Metrics

MoonshotScore: 46/100

Company Profile

CEO: Emmanuel Tsoupanarias
Headquarters: New York City, US
Employees: 1
Founded: 1998

AI Insight

AI analysis pending for MHTX

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Manhattan Scientifics, Inc. do?

Manhattan Scientifics, Inc. operates as a technology incubator, focusing on the development and commercialization of life-enhancing technologies in the fields of nano-technologies and nano-medicine. The company invests in early-stage ventures, providing resources and expertise to bring innovative medical solutions to market. Its business model centers around identifying promising technologies, nurturing their development, and ultimately commercializing them through licensing agreements, spin-offs, or internal development efforts. The company aims to improve medical treatments and diagnostics through nano-scale innovations.

What do analysts say about MHTX stock?

As of 2026-03-16, there is no available analyst coverage for Manhattan Scientifics, Inc. (MHTX). The company's small market capitalization and OTC listing may contribute to the lack of analyst interest. Investors should conduct their own due diligence and consider the risks associated with investing in early-stage, thinly traded companies. Key valuation metrics, such as P/E ratio, are currently negative, reflecting the company's lack of profitability. Growth considerations include the potential for successful commercialization of its nano-technology and nano-medicine initiatives.

What are the main risks for MHTX?

Manhattan Scientifics, Inc. faces several key risks, including the challenges of developing and commercializing early-stage technologies in the highly regulated medical device industry. The company's limited financial resources and small market capitalization increase its vulnerability to market fluctuations and funding shortfalls. Competition from established medical device companies poses a significant threat. Additionally, the company's success depends on obtaining regulatory approvals for its technologies, which can be a lengthy and uncertain process. The high beta of 9.94 indicates extreme volatility, making the stock susceptible to significant price swings.